

Intersect ENT Recognized for Gender Diversity by Watermark and UC Davis
Company Also Recognized in Deloitte's 2015 Technology Fast 500

MENLO PARK, Calif., November 17, 2015 – Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the company's inclusion in the inaugural Watermark Index, a collaboration between [Watermark](#), a leading Bay Area executive women's organization, and the University of California, Davis, honoring Bay Area companies that support the advancement of women and promote equal opportunity within their organizations.

Of the 223 largest public companies in the Bay Area, only 11 companies, including Intersect ENT, had women holding 30 percent or more of the top-five compensated executive positions and board seats.

In addition, the company announced that it ranked No. 8 on Deloitte's Technology [Fast 500](#),™ a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America.

"We are extremely proud of our record of growth and of the team that has made this possible," said Lisa Earnhardt, Intersect ENT's president and CEO. "One of our core values is diversity—in thought, gender, background and experience. We believe that diverse and differentiated views contribute to make us a better organization and inspire us on a daily basis."

"Silicon Valley, in the heart of the Bay Area, is a global hub of innovation and a top destination for some of the world's best talent," says Watermark CEO Marlene Williamson. "These companies – some of the largest in the world – have the opportunity to lead the rest of the business community by example in advancing gender diversity within the top ranks. The Watermark Index is pleased to showcase Intersect ENT for doing so."

About Intersect ENT

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL® and PROPEL® mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new steroid releasing implants designed to provide ENT physicians with even more customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.

For additional information on the company or the products including risks and benefits please visit www.intersectENT.com.

XENT-G

#

Inquiries: Jeri Hilleman
650.641.2105
ir@intersectENT.com

Nicole Osmer
650.454.0504
nicole@nicoleosmer.com